Clinical Trial

A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This multicenter, randomized, double-blind, placebo- and open-label active comparator-controlled, parallel-group, dose-range-finding, Phase II study aims to evaluate the efficacy, tolerability, and safety of RO7795081 for glycemic control in adult participants with Type 2 diabetes mellitus (T2D).
Protocol Amendment History 3 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-04-09
notable Primary completion moved earlier: 2027-02-08 -> 2026-11-27 2026-04-09
minor Completion moved earlier: 2027-02-08 -> 2026-11-27 2026-04-09
Trial Details
NCT Number NCT07112872
Lead Sponsor Hoffmann-La Roche
Conditions Type 2 Diabetes Mellitus
Enrollment 240 participants
Start Date 2025-08-19
Primary Completion 2026-11-27 (estimated)
Study Completion 2026-11-27 (estimated)
Updated on ClinicalTrials.gov 2026-07-07